文献速递前列腺癌

前列腺癌三维模型的临床潜力:系统综述

Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review.
PubMed 文献 · Eur Urol Oncol · 2026-04-02

该系统综述评估患者来源类器官(PDO)和器官型切片组织作为前列腺癌(PCa)三维(3D)模型的可行性、分子保真度及转化应用。PDO建立成功率变异大(15-90%),仅少数模型可长期扩增超过5-10代,但PDO在基因组、转录组和表观遗传上与患者肿瘤高度一致,可用于生物标志物探索和药物筛选,缺点为缺乏微环境成分且建立耗时。

要点

  • PDO建立成功率15-90%,受样本类型、疾病分期和基质条件影响。
  • 仅少数模型(尤其来自根治性前列腺切除术)可长期扩增超过5-10代。
  • PDO保留瘤内异质性,适用于单细胞测序和药物反应预测。

核心结论

  • 前列腺癌3D模型是研究肿瘤生物学、预测药物反应和识别新生物标志物的患者特异性平台,但标准化和可扩展性挑战仍存。

主要发现

  • PDO建立成功率范围为15-90%,受样本类型、疾病分期和基质条件影响。
  • 仅少数模型可实现超过5-10代的长期扩增,尤其来自根治性前列腺切除术的模型。
  • PDO在基因组、转录组和表观遗传上与患者肿瘤高度一致,包括AR信号、TP53、PTEN、PI3K/AKT和神经内分泌标志物的关键改变。
  • PDO保留瘤内异质性,适用于单细胞测序。
  • 生物标志物研究识别EZH2、SCG2、HER3和甲基化模式与亚型分类相关。

临床怎么用

  • PDO可用于患者特异性药物反应预测和生物标志物探索,但需注意成功率变异大且长期扩增受限。
  • 药物筛选结果可提示对AR通路抑制剂、紫杉烷类、PARP抑制剂和PI3K/AKT靶向治疗的差异敏感性,辅助耐药机制研究。

局限性

  • 缺乏微环境成分。
  • 类器官建立耗时。
  • 标准化和可扩展性挑战持续存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient-derived organoids (PDOs) and organotypic slice tissues have emerged as promising platforms to model prostate cancer (PCa) in three dimensions (3D), preserving tumor architecture and molecular features. Their relevance as translational tools for precision oncology, however, remains incompletely defined. OBJECTIVE: To systematically assess the feasibility, molecular fidelity, and translational applications of 3D models in PCa. METHODS: We conducted a comprehensive systematic literature review (PROSPERO CRD42025643117) in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies published until December 2024 were screened across PubMed, EMBASE, and Web of Science. Original studies involving human-derived PCa 3D models were included. Data were extracted on organoid generation efficiency, molecular profiling, biomarker exploration, and drug testing outcomes. KEY FINDINGS AND LIMITATIONS: Success rates for PDO establishment varied widely (15-90%), influenced by sample type, disease stage, and matrix conditions. Long-term expansion beyond 5-10 passages was achieved in a minority of models, particularly from radical prostatectomy. Despite these limitations, PDOs showed high genomic, transcriptomic, and epigenetic concordance with patient tumors, including key alterations in androgen receptor (AR) signaling, Tumor Protein (TP) 53, Phosphatase and TENsin homolog (PTEN), Phosphoinositide-3-Kinase/Protein Kinase B (PI3K/AKT), and neuroendocrine markers. Organoids retained intratumoral heterogeneity and were suitable for single-cell sequencing. Biomarker studies identified Enhancer of Zest Homolog 2 (EZH2), SeCretoGranin 2 (SCG2), Human Epidermal Growth factor receptor 3 (HER3), and methylation patterns as relevant for subtype classification. Drug screening recapitulated known therapeutic responses and highlighted actionable resistance mechanisms, including differential sensitivity to androgen receptor pathway inhibitors, taxanes, poly(adenosine diphosphate-ribose)-polymerase inhibitors, and PI3K/AKT-targeted therapies. However, the lack of microenvironment components and the time-intensive nature of organoid establishment remain key limitations. CONCLUSIONS AND CLINICAL IMPLICATIONS: Prostate cancer 3D models offer a relevant, patient-specific platform to study tumor biology, predict drug responses, and identify novel biomarkers. While standardization and scalability challenges persist, organoids have a strong potential for integration into precision oncology pipelines.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Peyrottes A, de Brek N, Vieira Aleixo AS, et al. Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review. Eur Urol Oncol. 2026. PMID: 41927412. doi:10.1016/j.euo.2026.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。